Category Archives: Mesenchymal Stem Cells

Contact Information Available for logged-in reporters only Newswise In a first-of-its-kind collaboration, the University of California, Los Angeles, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and University of California, Irvine Sue & Bill Gross Stem Cell Research Center received a five year $8M grant from the California Institute of Regenerative Medicine (CIRM), the states stem cell agency, to establish a CIRM Alpha Stem Cell Clinic center of excellence to conduct clinical trials for investigational stem cell therapies and provide critical resources and expertise in clinical research. The $8M grant was one of three awarded today by CIRM as part of the CIRM Alpha Stem Cell Clinics (CASC) Network Initiative. The joint UCLA/UCI award under the direction of Dr. John Adams, a member of the UCLA Broad Stem Cell Research Center and professor in the department of orthopaedic surgery, will accelerate the implementation of clinical trials and delivery of stem cell therapies by providing world-class, state-of-the-art infrastructure to support clinical research. CIRM grant reviewers lauded the UCLA/UCI Consortiums impressive and multidimensional team of experienced personnel that will expand access to patients, attracting national and international clinical trials and accelerating future trials in the pipeline. The initial … Continue reading →

UCSD oncologist/researcher Catriona Jamieson is principal investigator for the university's $8 million stem cell grant. (See correction note at end). To speed up the quest to bring stem cell therapies to patients, a state agency on Thursday granted $8 million each to three academic medical centers pursuing "translational" work -- UC San Diego, UC Los Angeles and City of Hope in Duarte. The California Institute for Regenerative Medicine voted 10-1 to fund the "alpha" stem cell clinics, which are intended to bring stem cell treatments to the public. UC San Diego's proposal supports two stem cell-based clinical trials, both already underway. Catriona Jamieson, an oncologist at the university, is the principal investigator for the grant. One, a treatment for Type 1 diabetes, was developed by San Diego's ViaCyte. The other, for spinal cord injuries is being conducted by Neuralstem of Germantown, Md. In October, UCSD treated the first patient in the trial at the university's Sanford Stem Cell Clinical Center. The stem cell agency, commonly called CIRM, has focused heavily on basic research since its founding by California voters in 2004. But in recent years, the public has become more anxious to see the fruits of $3 billion in bond … Continue reading →

Meet the Researcher - Oct. 8, 2014 Researchers in the Center for Regenerative Medicine are studying the use of intraspinal deliver of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with ALS using a dose-escal... By: Mayo Clinic … Continue reading →

Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce Do It Yourself - Stem Cell Hair Therapy : http://placesiana.com/stem-cell-hair-loss-therapy Imagine becoming a healthier, much younger, better looking you? Infused with a potent growth factor... By: Sam Jeunesse … Continue reading →

By C. Rajan, contributing writer The University of Pennsylvania has announced promising results of its novel chimeric antigen receptor (CAR) therapy for cancer. In the study involving 25 children and five adults with end-stage acute lymphoblastic leukemia (ALL), there was an impressive 90 percent response rate with complete remission. Twenty-seven of the 30 patients went into complete remission after receiving the investigational therapy (called CTL019), and 78 percent of the patients were alive six months after treatment. The longest remission among the patients has lasted almost three years. The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants. Their cancers were so aggressive they had no treatment options left, said the studys senior author, Stephan Grupp, MD, PhD, at the Children's Hospital of Philadelphia. The durable responses we have observed with CTL019 therapy are unprecedented. The ongoing study is being conducted by researchers at the Childrens Hospital of Philadelphia and the Hospital of the University of Pennsylvania (Penn). The CAR trial program enrolling children with leukemia is also expanding to nine other pediatric centers. The experimental CAR therapy received FDAs breakthrough designation in July … Continue reading →

Contact Information Available for logged-in reporters only Newswise BOSTON It is an intricate network of activity that enables breast cancer cells to move from the primary breast tumor and set up new growths in other parts of the body, a process known as metastasis. Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has identified an unexpected link between a transcription factor known to regulate speech and language development and metastatic colonization of breast cancer. Currently described online in Cell Stem Cell, the new findings demonstrate that, when silenced, the FOXP2 transcription factor, otherwise known as the speech gene, endows breast cancer cells with a number of malignant traits and properties that enable them to survive and thrive. We have identified a previously undescribed function for the transcription factor FOXP2 in breast cancer, explains senior author Antoine Karnoub, PhD, an investigator in the Department of Pathology at BIDMC and Assistant Professor of Pathology at Harvard Medical School. We have found that depressed FOXP2 [a member of the forkhead family of transcriptional regulators] and elevated levels of its upstream inhibitor microRNA 199a are prominent features of clinically advanced breast cancers that associate with poor patient survival. … Continue reading →

Bone Marrow-Derived Stem Cell Prolotherapy Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing. Stem cells are the repairmen... By: Kab S. Hong M.D. … Continue reading →

Dr Charles Krome Stem Cell Therapy This video is about Dr Charles Krome Stem Cell Therapy. By: John lore … Continue reading →

PUBLIC RELEASE DATE: 16-Oct-2014 Contact: Anita Srikameswaran SrikamAV@upmc.edu 412-578-9193 University of Pittsburgh Schools of the Health Sciences @UPMCnews PITTSBURGH, Oct. 16, 2014 Despite previous indications to the contrary, the esophagus does have its own pool of stem cells, said researchers from the University of Pittsburgh School of Medicine in an animal study published online today in Cell Reports. The findings could lead to new insights into the development and treatment of esophageal cancer and the precancerous condition known as Barrett's esophagus. According to the American Cancer Society, more than 18,000 people will be diagnosed with esophageal cancer in the U.S. in 2014 and almost 15,500 people will die from it. In Barrett's esophagus, the lining of the esophagus changes for unknown reasons to resemble that of the intestine, though gastro-esophageal reflux disease or GERD is a risk factor for its development. "The esophageal lining must renew regularly as cells slough off into the gastrointestinal tract," said senior investigator Eric Lagasse, Pharm.D., Ph.D., associate professor of pathology, Pitt School of Medicine, and director of the Cancer Stem Cell Center at the McGowan Institute for Regenerative Medicine. "To do that, cells in the deeper layers of the esophagus divide about twice a … Continue reading →

16 hours ago by Vicky Just Naive-like stem cells could potentially be used to treat dementia or reduce organ transplants Scientists from our university and Berlin have identified a type of human stem cell that appears to be "nave-like" able to develop into any type of cell. The discovery of this cell type could potentially have a large impact on our understanding of how humans develop and on the field of regenerative medicine. The human embryonic stem cells (ESCs) that scientists currently study in the lab are able to develop into several different types of cell but are already pre-determined to some extent. Published in the top scientific journal Nature, researchers from the Max Delbrck Centre for Molecular Medicine (MDC), Berlin, Germany and our university have for the first time discovered human ESCs that appear to behave like "nave" cells able to develop into any type of cell. These nave-like cells, only previously found in mice, are easy to grow in the lab and could have huge potential for regenerating damaged tissues in the body, potentially leading to treatments for diseases such as dementia or reducing the need for organ transplantation. Professor Laurence Hurst from our Department of Biology & … Continue reading →